Use of Raltegravir in Pediatric HIV-1 Infection

Marcia L. Buck, Pharm.D., FCCP, FPPAG; Kristi N. Hofer, Pharm.D; Michelle W. McCarthy, Pharm.D.; FASHP Susan B. Cogut, Pharm.D


Pediatr Pharm. 2012;18(1) 

In This Article

Adverse Effects

In clinical trials conducted in adults, the most commonly reported adverse effects with raltegravir have included insomnia in 4% of patients, and headache, neutropenia, anemia, or thrombocytopenia in 1–2%. Other adverse effects included dizziness, fatigue, pruritus, nausea, and diarrhea. Less common adverse effects included anxiety, depression, asthenia, abdominal pain, and vomiting (all occurring in < 2% of patients). Elevated serum aminotransferases, bilirubin, glucose, and lipid values occurred in 1–6% of patients. Rates of discontinuation in clinical trials have been no different in the raltegravir and placebo groups. Post-marketing reports include rare cases of elevated creatine kinase, myopathy, and rhabdomyolysis, as well as nephrolithiasis, renal and liver failure, and hypersensitivity or severe dermatologic reactions.[2–5]

The manufacturer reports that the adverse effects documented in children participating in the IMPAACT P1066 trial were similar to those seen in adults.[3] One child experienced hyperactivity and insomnia and another experienced a serious allergic rash. One patient experienced elevated serum aminotransferases.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: